Client

Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research. Jason Kolbert at Dawson James Securities. Vernon...

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is gone -...

Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to 115 days...

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we follow, shows a spike in either...

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever! We're adding Citius Pharma to the Watch...

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class...

Asia Broadband, Gold Play With Digital Currency (NFT) Twist The last speculative stock trading under $0.05, that we added to the Watch List was Pharamather...

Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine candidate on Thursday, April 4, 2024, 12:00...

Taking advantage of post reverse-split investor pessimism, is a VALID investing technique. Altamira is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to...